Making biotech profitable.

Worldwide developments in biotechnology have shown that it takes far more to make a profitable company than just promising research results or product ideas. The timescale and capital requirements for a product to reach maturity and marketability had frequently been greatly underestimated by both entrepreneurs and investors. The consequences of such a misjudgment are quite often insolvency, or at least the need to re-orientate towards a more conventional trading or services company, which is also towards a heavily reduced value creation. For those investors involved who justifiably expect above-average returns from the venture capital they have invested, previous developments in the biotechnology branch were disappointing in many respects.
"We help entrepreneurs and investors to obtain the highest possible long-term interest on the venture capital they have invested, using the existing resources of young biotechnology companies. Our success-related payment models guarantee an optimal cost-benefit ratio, thus ensuring the future success of your company." Christian Tidona, PhD Managing Director